UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 9, 2004
DOR BioPharma, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
0-8672 |
|
41-1505029 |
|
|
|
|
|
|
|
|
|
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
|
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
|
| |
|
|
|
|
|
1691 Michigan, Suite 435, Miami, FL |
|
33139 |
|
|
|
|
|
|
|
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
Registrant’s telephone number, including area code (305) 534-3383
Not applicable
(Former name or former address, if changed since last report)
Item 5. Other Events and Regulation FD Disclosure
On July 9, 2004, the registrant announced that their CEO Ralph Ellison has resigned for personal reasons.
A copy of the press release dated July 9, 2004 is filed herewith as Exhibit 99.1.
Exhibits
99.1 Press Release of DOR BioPharma, Inc regarding the Private Placement Financing
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
DOR BioPharma, Inc. |
|
|
|
Date: July 13, 2004 |
|
By: /s/Geoff Green
Geoff Green
President |
|
|
|
|
|
End of Filing